| Name | Title | Contact Details |
|---|
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
BioStar Consulting, Inc. is a Greenbrier, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.